Data / Research funding / Hematology
Hematology: 5,469 NIH awards ($6.8B) to 651 organizations
5,469 NIH awards ($6.8B) in the NIH spending category Hematology, to 651 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 5,469 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| COG NCTN Year 12 BIQSFP Progress Report | NIH | National Cancer Institute | 2021 to 2025 | $141,250,012 | April 11, 2014 | February 28, 2026 | HAWKINS, DOUGLAS S. | reporter.nih.gov |
| NCI Early Career Cancer Clinical Investigator Award | NIH | National Cancer Institute | 2021 to 2025 | $65,560,307 | March 10, 1997 | November 30, 2026 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Alliance for Clinical Trials in Oncology Operations Center - GY11 BIQSFP Funded Extension | NIH | National Cancer Institute | 2021 to 2025 | $65,300,792 | April 17, 2014 | February 28, 2026 | PIANTADOSI, STEVEN | reporter.nih.gov |
| Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $39,483,481 | September 18, 2018 | July 31, 2028 | LAM, WILBUR A | reporter.nih.gov |
| Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $36,418,175 | September 15, 2017 | August 31, 2031 | HAMADANI, MEHDI HUSSAIN | reporter.nih.gov |
| Children's Oncology Group | NIH | National Cancer Institute | 2023 to 2025 | $31,354,180 | March 1, 2023 | February 28, 2026 | ALONZO, TODD A | reporter.nih.gov |
| A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research | NIH | National Cancer Institute | 2021 to 2025 | $30,268,190 | March 1, 1998 | February 29, 2028 | SHAW, BRONWEN | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,642,385 | September 12, 1997 | November 30, 2025 | RATHMELL, WENDY KIMRYN | reporter.nih.gov |
| NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $27,888,290 | September 23, 2025 | September 22, 2026 | OSBORNE, C KENT | reporter.nih.gov |
| Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $26,536,563 | September 1, 2021 | May 31, 2028 | HOH, BRIAN LIM | reporter.nih.gov |
| CCSG - Administrative Supplement - ECIA | NIH | National Cancer Institute | 2021 to 2025 | $22,920,176 | September 1, 1997 | March 31, 2029 | ODUNSI, KUNLE | reporter.nih.gov |
| MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE | NIH | National Cancer Institute | 2023 to 2025 | $22,579,077 | September 22, 2025 | September 21, 2027 | reporter.nih.gov | |
| RURAL: Risk Underlying Rural Areas Longitudinal Cohort Study | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $21,300,494 | May 15, 2019 | April 30, 2026 | RAMACHANDRAN, VASAN | reporter.nih.gov |
| Nebraska Research Network in Functional Genomics | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,833,603 | September 30, 2001 | April 30, 2026 | SORGEN, PAUL L | reporter.nih.gov |
| ECOG-ACRIN Biospecimen Bank to Support NCTN | NIH | National Cancer Institute | 2021 to 2025 | $20,630,107 | April 29, 2015 | March 31, 2027 | JEWELL, SCOTT D | reporter.nih.gov |
| Cure Sickle Cell | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $19,980,036 | September 28, 2018 | September 30, 2026 | EAPEN, MARY | reporter.nih.gov |
| Baylor College of Medicine Cancer Center - Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $19,034,443 | July 1, 2007 | June 30, 2030 | REDDY, PAVAN | reporter.nih.gov |
| Center for Quantitative Biology: A focus on "omics", from organisms to single cells | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $17,122,562 | August 1, 2019 | June 30, 2029 | WHITFIELD, MICHAEL L | reporter.nih.gov |
| NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) ADMINISTRATIVE COORDINATING CENTER (ACC) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $16,650,520 | August 23, 2021 | August 22, 2026 | SHIFFLETT, PATRICIA | reporter.nih.gov |
| Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $16,153,090 | May 1, 2023 | April 30, 2029 | SELF, WESLEY H | reporter.nih.gov |
| Immune signatures of vaccine responses in vulnerable populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,275,325 | July 12, 2010 | April 30, 2028 | MONTGOMERY, RUTH R | reporter.nih.gov |
| The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (REACT-AF) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $14,978,926 | August 25, 2022 | July 31, 2029 | PASSMAN, ROD S | reporter.nih.gov |
| The Tisch Cancer Institute - Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $14,629,412 | August 1, 2015 | July 31, 2030 | PARSONS, RAMON E | reporter.nih.gov |
| Children's Oncology Group Pediatric Early Phase Clinical Trial Network | NIH | National Cancer Institute | 2021 to 2024 | $14,041,303 | May 3, 2024 | July 31, 2024 | WEIGEL, BRENDA J. | reporter.nih.gov |
| CURE SICKLE CELL INITIATIVE DATA STRATEGY AND DATA RESOURCES PROGRAM | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $13,440,748 | September 28, 2018 | December 31, 2026 | KRONER, BARBARA L | reporter.nih.gov |
| Collaborative Pediatric Critical Care Research Network | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $12,717,344 | August 13, 2021 | July 31, 2026 | WATT, KEVIN M | reporter.nih.gov |
| (EET Biobank) NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank | NIH | National Cancer Institute | 2021 to 2025 | $11,843,510 | September 1, 2020 | March 31, 2027 | NICOL, KATHLEEN | reporter.nih.gov |
| Characterizing pediatric genomes through an optimized sequencing approach | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $11,335,114 | September 23, 2016 | August 31, 2025 | GRIMWOOD, JANE | reporter.nih.gov |
| COBRE in Human Genetics | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $10,847,075 | February 10, 2021 | January 31, 2027 | MACKAY, TRUDY F. | reporter.nih.gov |
| The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study | NIH | National Cancer Institute | 2021 to 2025 | $10,080,862 | June 23, 2015 | March 31, 2026 | CERHAN, JAMES R | reporter.nih.gov |
| Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $9,739,425 | September 1, 2022 | April 30, 2027 | GLADWIN, MARK T | reporter.nih.gov |
| Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE) | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $9,111,057 | July 1, 2019 | April 30, 2027 | SHETH, KEVIN NAVIN | reporter.nih.gov |
| RURAL: Risk Underlying Rural Areas Longitudinal Cohort Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $8,923,910 | May 15, 2019 | April 30, 2025 | RAMACHANDRAN, VASAN S | reporter.nih.gov |
| FRAMINGHAM HEART STUDY (FHS), TASK AREA A - CORE STUDY OPERATIONS | NIH | National Heart, Lung, and Blood Institute | 2025 | $8,894,939 | February 14, 2025 | February 13, 2026 | LLOYD-JONES, DONALD | reporter.nih.gov |
| Comprehensive characterization of variants underlying heart and blood diseases with CRISPR base editing | NIH | National Human Genome Research Institute | 2021 to 2025 | $8,671,281 | September 1, 2021 | May 31, 2027 | PINELLO, LUCA | reporter.nih.gov |
| Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis Pathobiology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $8,479,606 | May 1, 2021 | April 30, 2027 | EFRON, PHILIP A | reporter.nih.gov |
| 1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $8,010,367 | September 16, 2020 | August 31, 2025 | BOECKH, MICHAEL J | reporter.nih.gov |
| Implementation Research Strategies for Heart, Lung, and Blood Co-morbidities in People Living with HIV - Research Coordinating Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $7,961,623 | September 30, 2020 | August 31, 2025 | SCHECHTMAN, KENNETH B. | reporter.nih.gov |
| Phosphate binder therapy and chronic kidney disease in children | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,929,421 | June 15, 2020 | April 30, 2026 | SALUSKY, ISIDRO B. | reporter.nih.gov |
| "REAL Answers" (Registry Expansion Analyses to Learn) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $7,362,213 | August 20, 2023 | July 31, 2028 | GLASSBERG, JEFFREY AVINS | reporter.nih.gov |
| IGF::OT::IGF TASK AREA A - MAINTAINING AND ENHANCING THE BIOLINCC PROGRAM | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $7,272,737 | November 16, 2023 | November 15, 2025 | GIFFEN, CAROL | reporter.nih.gov |
| TRANSPIRE: A Prospective Cohort Study of Lung Injury After Hematopoietic Stem Cell Transplant in Children. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $7,251,380 | September 1, 2021 | May 31, 2027 | DAVIES, STELLA MARGARET | reporter.nih.gov |
| Endothelial Dysfunction and Restoration in Trauma Induced Coagulopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $7,179,267 | September 15, 2023 | August 31, 2028 | NEAL, MATTHEW D | reporter.nih.gov |
| Sickle Cell Disease Cure Initiative (SCDC) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $7,000,926 | September 30, 2017 | June 30, 2026 | COLEMAN-COWGER, VICTORIA HOPE | reporter.nih.gov |
| Multi-arm Optimization of Stroke Thrombolysis (MOST) Stroke Trial | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $6,997,609 | May 1, 2021 | October 31, 2024 | ADEOYE, OPEOLU M | reporter.nih.gov |
| 1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,920,555 | September 20, 2020 | August 31, 2026 | MORRIS, CLAUDIA R | reporter.nih.gov |
| Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,892,629 | September 15, 2004 | August 31, 2025 | FARRIS, A DARISE | reporter.nih.gov |
| Resuscitation Strategies for Achieving Thrombo-inflammatory Homeostasis | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $6,845,824 | May 20, 2019 | April 30, 2026 | COHEN, MITCHELL | reporter.nih.gov |
| The 10,000 Families Cohort: a new study to understand the environmental causes of cancer | NIH | National Cancer Institute | 2023 to 2025 | $6,827,634 | September 24, 2021 | August 31, 2028 | POYNTER, JENNY N. | reporter.nih.gov |
| A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $6,768,642 | September 21, 2022 | August 31, 2025 | JOHNSEN, JILL MARIE | reporter.nih.gov |
| Washington University/Siteman Cancer Center Lead Academic Site | NIH | National Cancer Institute | 2021 to 2025 | $6,572,668 | March 5, 2019 | February 28, 2026 | BARTLETT, NANCY L | reporter.nih.gov |
| Establishing and Interpreting Abnormal DNA Methylation in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $6,541,625 | January 1, 2017 | June 30, 2030 | JONES, PETER A | reporter.nih.gov |
| The Darbepoetin Kindergarten Development Study | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $6,538,886 | September 1, 2023 | August 31, 2028 | BANN, CARLA M | reporter.nih.gov |
| Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,498,374 | August 1, 2017 | July 31, 2027 | WARE, RUSSELL E | reporter.nih.gov |
| Molecular Circuits in the Hematopoietic Stem Cell Niche | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $6,422,507 | August 15, 2020 | May 31, 2025 | DALEY, GEORGE Q | reporter.nih.gov |
| Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA) | NIH | Fogarty International Center | 2021 to 2025 | $6,419,538 | September 15, 2021 | June 30, 2027 | HAPPI, CHRISTIAN T. | reporter.nih.gov |
| Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | NIH | National Cancer Institute | 2021 to 2025 | $6,371,380 | September 1, 2021 | June 30, 2027 | BROOKS, DAVID G | reporter.nih.gov |
| Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $6,352,490 | September 21, 2020 | August 31, 2025 | DOORENBOS, ARDITH Z | reporter.nih.gov |
| Synergistic role of signaling and epigenetics in leukemic transformation | NIH | National Cancer Institute | 2021 to 2025 | $6,322,598 | January 17, 2017 | July 31, 2030 | LEVINE, ROSS L | reporter.nih.gov |
| Translating genomic discoveries to improved outcomes for high risk acute leukemia | NIH | National Cancer Institute | 2021 to 2025 | $6,239,168 | January 19, 2017 | August 31, 2030 | MULLIGHAN, CHARLES G | reporter.nih.gov |
| 2/2 REACT-AF: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $6,043,000 | August 25, 2022 | July 31, 2029 | HANLEY, DANIEL F | reporter.nih.gov |
| Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $5,977,497 | August 15, 2022 | July 31, 2027 | KANTER, JULIE | reporter.nih.gov |
| Metabolic gatekeepers in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $5,936,594 | April 1, 2016 | August 31, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Multimodal histologic atlas of human bone marrow | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $5,888,084 | August 1, 2022 | June 30, 2026 | BENDALL, SEAN CURTIS | reporter.nih.gov |
| Novel Biologic Therapies for GVHD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,851,412 | February 1, 2010 | June 30, 2026 | KEAN, LESLIE S | reporter.nih.gov |
| 1/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $5,835,271 | September 15, 2023 | August 31, 2028 | RAO, SUNIL V | reporter.nih.gov |
| Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,640,067 | August 5, 2022 | July 31, 2029 | STEINBACH, WILLIAM J | reporter.nih.gov |
| OSU as a Network Lead Academic Participating Site for the NCI NCTN | NIH | National Cancer Institute | 2021 to 2025 | $5,610,699 | March 28, 2019 | February 28, 2026 | VERSCHRAEGEN, CLAIRE F. | reporter.nih.gov |
| Mutographs differentiating the inheritance and temporal onset of multiple myeloma | NIH | National Cancer Institute | 2021 to 2025 | $5,575,548 | August 11, 2021 | July 31, 2026 | MORGAN, GARETH JOHN | reporter.nih.gov |
| Myeloma multidimensional precancer atlas | NIH | National Cancer Institute | 2024 to 2025 | $5,566,942 | September 18, 2024 | August 31, 2029 | GHOBRIAL, IRENE M. | reporter.nih.gov |
| NHLBI MAINTENANCE OF CANINE MODELS OF HUMAN BLEEDING DISORDERS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $5,542,798 | September 20, 2019 | September 19, 2024 | NICHOLS, TIMOTHY | reporter.nih.gov |
| NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | NIH | National Cancer Institute | 2021 to 2025 | $5,422,908 | March 5, 2019 | February 28, 2026 | BURSTEIN, HAROLD JOHN | reporter.nih.gov |
| The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network | NIH | National Cancer Institute | 2021 to 2025 | $5,286,341 | March 28, 2014 | February 28, 2027 | CARSON, WILLIAM E. | reporter.nih.gov |
| New Mechanistic Insights & Therapeutic Applications of Megakaryocytes/Platelets | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,258,818 | May 1, 2020 | April 30, 2027 | PONCZ, MORTIMER | reporter.nih.gov |
| System Wide Operations for Rare Disorders (SWORD) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $5,227,397 | September 30, 2009 | June 30, 2025 | KIM, HELEN | reporter.nih.gov |
| CureSC Manufacturing Resource Platform | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $5,179,238 | September 27, 2019 | September 30, 2026 | CARDOSO, ANGELO A. | reporter.nih.gov |
| SHIPSS: Stress Hydrocortisone In Pediatric Septic Shock | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $5,170,974 | July 1, 2019 | June 30, 2025 | AGUS, MICHAEL SD | reporter.nih.gov |
| Hematology Central Coordinating Center (HCCC) for the NIDDK Hematology Centers Program | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $5,166,827 | September 1, 2020 | July 31, 2030 | BEAUDIN, ANNA E | reporter.nih.gov |
| Reading mitochondrial apoptotic signaling to identify active cancer therapeutics | NIH | National Cancer Institute | 2021 to 2025 | $5,159,959 | August 1, 2019 | September 29, 2025 | LETAI, ANTHONY G | reporter.nih.gov |
| Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA) | NIH | National Cancer Institute | 2024 to 2025 | $5,130,804 | September 1, 2024 | August 31, 2029 | FAN, RONG | reporter.nih.gov |
| Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $5,128,451 | September 1, 2023 | June 30, 2027 | FREDRICKS, DAVID NEAL | reporter.nih.gov |
| Novel Strategies to Improve Blood Transfusion Practice | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $5,119,758 | August 15, 2022 | July 31, 2027 | LUO, HONGBO R | reporter.nih.gov |
| Precision approaches to refining TP53-associated cancer risk | NIH | National Cancer Institute | 2021 to 2023 | $5,115,949 | September 18, 2019 | August 31, 2025 | GRUBER, STEPHEN B | reporter.nih.gov |
| Strategy for Improving Stroke Treatment Response (SISTER) Trial | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $5,110,320 | July 1, 2023 | June 30, 2024 | KHATRI, POOJA | reporter.nih.gov |
| Towards targeting the lymphoma microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $5,082,235 | September 1, 2020 | August 31, 2027 | WENDEL, HANS-GUIDO | reporter.nih.gov |
| Mucus-degrading intestinal bacteria and toxicities of hematopoietic cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $5,032,505 | September 21, 2024 | July 31, 2029 | JENQ, ROBERT | reporter.nih.gov |
| Identifying the mechanisms of leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $5,032,279 | September 22, 2021 | August 31, 2028 | CRISPINO, JOHN D | reporter.nih.gov |
| 1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $5,023,972 | April 1, 2022 | March 31, 2029 | SHAW, BRONWEN | reporter.nih.gov |
| Strategy for Improving Stroke Treatment Response (SISTER) Trial | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $4,963,344 | July 1, 2023 | June 30, 2028 | KHATRI, POOJA | reporter.nih.gov |
| Single-cell genomic profiling to identify immune signatures of bacterial sepsis in humans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,956,855 | March 3, 2021 | February 28, 2027 | GOLDBERG, MARCIA B | reporter.nih.gov |
| Puerto Rico NCI Community Oncology Research Program (Puerto Rico NCORP) | NIH | National Cancer Institute | 2021 to 2025 | $4,943,161 | August 22, 2014 | July 31, 2026 | SANTOS-REYES, LUIS JAVIER | reporter.nih.gov |
| Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $4,937,681 | May 6, 2022 | April 30, 2027 | SCOTT, JESSICA | reporter.nih.gov |
| Targeting the MYC Pathway for the Treatment of Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,931,456 | September 8, 2020 | August 31, 2027 | FELSHER, DEAN W | reporter.nih.gov |
| IGF::OT::IGF THE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) NATURAL HISTORY STUDY, DATA COORDINATING CENTER (DCC), TASK ORDER 03, SEPTEMBER 1, 2016-FEBRUARY 28, 2018 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,930,056 | September 1, 2016 | December 31, 2025 | STABLIN, DON | reporter.nih.gov |
| The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations | NIH | National Cancer Institute | 2021 to 2025 | $4,888,860 | September 1, 2016 | August 31, 2030 | KAELIN, WILLIAM G. | reporter.nih.gov |
| Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,879,349 | July 1, 2023 | June 30, 2026 | NGUYEN, THERESA | reporter.nih.gov |
| 1/2 Trauma Resuscitation with Group O Whole Blood Or Products (TROOP) Trial | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $4,870,584 | August 5, 2022 | July 31, 2027 | JANSEN, JAN O | reporter.nih.gov |
| Mechanisms of integrin signaling and a new anti-platelet/anti-inflammatory approach | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,858,002 | June 1, 2020 | May 31, 2027 | DU, XIAOPING | reporter.nih.gov |
| Investigating the heterogeneity and coordination of hematopoietic stem cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,840,269 | August 1, 2020 | July 31, 2027 | LU, RONG | reporter.nih.gov |
| Vasculo-neuronal pathophysiological interface in Alzheimer’s and Atherosclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $4,815,513 | September 18, 2024 | August 31, 2027 | IRUELA-ARISPE, M. LUISA | reporter.nih.gov |
| From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $4,812,450 | September 12, 2023 | July 31, 2030 | DALLA-FAVERA, RICCARDO | reporter.nih.gov |
| A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $4,780,411 | April 5, 2019 | March 31, 2026 | WILCOX, DAVID ALLEN | reporter.nih.gov |
| Sickle Africa Data Coordinating Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,779,335 | April 1, 2017 | April 30, 2027 | WONKAM, AMBROISE | reporter.nih.gov |
| Novel signaling molecules regulating platelet activation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,746,717 | June 1, 2021 | May 31, 2028 | KUNAPULI, SATYA P. | reporter.nih.gov |
| Severe Chronic Neutropenia International Registry | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,709,229 | August 1, 2025 | July 31, 2027 | SHIMAMURA, AKIKO | reporter.nih.gov |
| Development of Innovative Resources to Advance MDS Research | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $4,661,966 | September 15, 2023 | July 31, 2028 | BLEAKLEY, MARIE | reporter.nih.gov |
| Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $4,660,810 | May 1, 2023 | April 30, 2027 | CHEN, RIDONG | reporter.nih.gov |
| Platelet Exocytosis and Endocytosis in Thrombosis and Immunity | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,637,191 | April 1, 2020 | March 31, 2027 | WHITEHEART, SIDNEY WALDO | reporter.nih.gov |
| Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,613,595 | June 3, 2022 | May 31, 2027 | KAWAI, TATSUO | reporter.nih.gov |
| Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $4,603,890 | June 15, 2022 | May 31, 2027 | TYNER, JEFFREY WALLACE | reporter.nih.gov |
| Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting | NIH | National Cancer Institute | 2021 to 2025 | $4,594,192 | September 1, 2021 | August 31, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| Molecular Pathogenesis of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $4,591,274 | August 13, 2015 | June 30, 2029 | LEY, TIMOTHY J. | reporter.nih.gov |
| Tissue factor-dependent coagulation in thrombosis and immune responses | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,577,076 | February 1, 2021 | January 31, 2028 | MACKMAN, NIGEL | reporter.nih.gov |
| Therapeutic Targeting of Human AML Stem Cells | NIH | National Cancer Institute | 2021 to 2025 | $4,546,001 | September 8, 2020 | August 31, 2027 | JORDAN, CRAIG T. | reporter.nih.gov |
| Determinants of the racial/ethnic disparity in MGUS risk: An epidemiologic study in 4 cohorts | NIH | National Cancer Institute | 2021 to 2025 | $4,479,852 | September 20, 2021 | August 31, 2026 | COZEN, WENDY | reporter.nih.gov |
| Regulation of Protein C Pathways | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,441,427 | June 1, 2018 | March 31, 2026 | MOSNIER, LAURENT OLIVIER | reporter.nih.gov |
| 1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $4,424,844 | September 1, 2017 | August 31, 2025 | VEDANTHAM, SURESH | reporter.nih.gov |
| ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC) | NIH | National Cancer Institute | 2021 to 2025 | $4,374,283 | March 1, 2025 | February 28, 2026 | LEVINE, ROSS L | reporter.nih.gov |
| Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer | NIH | National Cancer Institute | 2021 to 2025 | $4,311,469 | July 12, 2018 | June 30, 2027 | CASTRO-GONZALEZ, CARLOS | reporter.nih.gov |
| Molecular and Translational Studies in Hematologic Disorders | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $4,297,096 | March 15, 2019 | February 28, 2025 | LOPEZ, JOSE ARON | reporter.nih.gov |
| Impact of Infection and Inflammation on Primitive Hematopoiesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,290,831 | July 1, 2021 | June 30, 2028 | KING, KATHERINE YUDEH | reporter.nih.gov |
| Porphyrias Consortium | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $4,280,404 | September 30, 2009 | June 30, 2025 | DESNICK, ROBERT J | reporter.nih.gov |
| The Role of the MBD2-NuRD Complex in Gamma-Globin Gene Silencing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,278,408 | August 1, 2018 | August 31, 2029 | GINDER, GORDON D | reporter.nih.gov |
| Mayo Clinic Center for Clinical Proteomics | NIH | National Cancer Institute | 2022 to 2025 | $4,271,766 | June 1, 2022 | May 31, 2027 | PANDEY, AKHILESH | reporter.nih.gov |
| Mechanisms of Platelet Activity in Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,269,155 | February 15, 2019 | January 31, 2027 | BERGER, JEFFREY S | reporter.nih.gov |
| Experimental Cerebral Hemorrhage: Mechanisms and Therapies | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $4,249,639 | May 1, 2020 | April 30, 2025 | XI, GUOHUA | reporter.nih.gov |
| The Centrosome as a master controller of platelet production. | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,226,760 | April 1, 2022 | March 31, 2029 | ITALIANO, JOSEPH E | reporter.nih.gov |
| A generalizable framework for linking single-cell genomic states with cell fate outcomes in hematopoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $4,203,696 | August 15, 2020 | May 31, 2025 | GRIMES, H. LEIGHTON | reporter.nih.gov |
| Small GTPases in the biology of platelets and megakaryocytes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,193,798 | March 21, 2019 | March 31, 2026 | BERGMEIER, WOLFGANG | reporter.nih.gov |
| The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL) | NIH | National Cancer Institute | 2022 to 2025 | $4,109,575 | September 8, 2022 | August 31, 2027 | SLAGER, SUSAN L | reporter.nih.gov |
| Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation | NIH | National Cancer Institute | 2022 to 2025 | $4,108,272 | September 6, 2022 | August 31, 2029 | GHOBRIAL, IRENE M. | reporter.nih.gov |
| AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenicstroke (ARCADIA) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $4,101,394 | May 1, 2017 | April 30, 2025 | MARSHALL, RANDOLPH S | reporter.nih.gov |
| Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical Insights | NIH | National Cancer Institute | 2022 to 2025 | $4,071,173 | June 1, 2022 | May 31, 2027 | ZHANG, BING | reporter.nih.gov |
| Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,065,243 | March 15, 2021 | February 28, 2027 | DEBAUN, MICHAEL R. | reporter.nih.gov |
| Integrative Training Program for Pediatric Sickle Cell Pain | NIH | National Center for Complementary & Integrative Health | 2024 | $4,030,343 | September 19, 2022 | August 31, 2027 | SIL, SOUMITRI | reporter.nih.gov |
| Base editing and prime editing for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,000,055 | January 1, 2021 | June 30, 2030 | WEISS, MITCHELL J | reporter.nih.gov |
| Combining Targeted RIT and Synergistic Novel Agent-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,984,924 | June 1, 2020 | May 31, 2027 | OROZCO, JOHNNIE JOSE | reporter.nih.gov |
| Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | NIH | National Cancer Institute | 2021 to 2025 | $3,984,664 | July 16, 2018 | January 31, 2027 | BICKEL, KELLIE | reporter.nih.gov |
| Bloodstream infection detection directly on whole blood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,982,842 | June 1, 2016 | June 30, 2027 | CELEDON, ALFREDO ANDRES | reporter.nih.gov |
| ZZ-3K3A-301: A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (RHAPSODY-2) | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $3,980,070 | June 1, 2022 | May 31, 2024 | LYDEN, PATRICK D | reporter.nih.gov |
| NextGen - CRI | NIH | National Cancer Institute | 2022 to 2025 | $3,968,330 | June 1, 2025 | May 31, 2026 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| The role of clonal hematopoiesis in the development and therapy of myeloid malignancies | NIH | National Cancer Institute | 2021 to 2024 | $3,926,618 | August 15, 2020 | November 1, 2024 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Basic Investigation and Translational Applications Concerning the Cell and Molecular Biology of Blood and Vascular Cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,926,545 | March 1, 2018 | February 28, 2026 | NEWMAN, PETER J | reporter.nih.gov |
| Targeting Epigenetic Circuits in B-Cell Lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $3,926,225 | September 13, 2018 | August 31, 2025 | MELNICK, ARI M. | reporter.nih.gov |
| Prevalence and persistence of the ETV6/RUNX1 pre-leukemic clone | NIH | National Cancer Institute | 2023 to 2025 | $3,924,430 | September 1, 2023 | August 31, 2028 | MARCOTTE, ERIN | reporter.nih.gov |
| Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,911,609 | August 1, 2015 | July 31, 2028 | KAPUR, REUBEN | reporter.nih.gov |
| NRSA Training Core | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $3,908,456 | September 1, 2023 | June 30, 2028 | HSU, CHI-YUAN | reporter.nih.gov |
| Novel Pediatric Sepsis Criteria and Clinical Decision Support Tools | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,901,596 | September 1, 2021 | May 31, 2030 | BENNETT, TELLEN | reporter.nih.gov |
| Genetic and therapeutic studies of hemostatic and thrombotic disorders using zebrafish | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,884,400 | April 1, 2020 | March 31, 2027 | SHAVIT, JORDAN A. | reporter.nih.gov |
| Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,880,499 | August 19, 2022 | July 31, 2029 | MEYER, NUALA JENNINGS | reporter.nih.gov |
| Generation of a temporal, spatial, and molecular map of in situ hematopoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,870,336 | September 15, 2022 | May 31, 2027 | CAMARGO, FERNANDO | reporter.nih.gov |
| Physician Scientist Training in Clinical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,870,097 | September 30, 1997 | June 30, 2030 | SCHUCHTER, LYNN M. | reporter.nih.gov |
| Engineering biophysical microtechnologies for hematologic applications in health and disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,836,413 | March 22, 2019 | February 28, 2027 | LAM, WILBUR A | reporter.nih.gov |
| Systems Biology of Bone Marrow Failure and MDS for Precision Medicine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,813,084 | September 15, 2019 | June 30, 2024 | SHIMAMURA, AKIKO | reporter.nih.gov |
| BMT Survivor Study-2 (BMTSS-2) | NIH | National Cancer Institute | 2021 to 2023 | $3,811,745 | April 1, 2019 | March 31, 2025 | BHATIA, SMITA | reporter.nih.gov |
| Contact Pathway Inhibitor to Prevent Vascular Access Failure | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,810,461 | June 1, 2023 | March 31, 2027 | LORENTZ, CHRISTINA U | reporter.nih.gov |
| GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,803,952 | September 1, 2021 | May 31, 2027 | HOTALING, JAMES | reporter.nih.gov |
| NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,793,717 | September 23, 2025 | September 22, 2026 | reporter.nih.gov | |
| Commensal microbiome impact on CD4 T cell lymphopenia in HIV-1 infection | NIH | National Institute on Aging | 2022 to 2025 | $3,776,712 | September 15, 2022 | May 31, 2027 | YOUNES, SOUHEIL ANTOINE | reporter.nih.gov |
| 2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,771,268 | May 15, 2019 | April 30, 2027 | BROOKS, MARIA MORI | reporter.nih.gov |
| Basic and Translational Studies in Redox Regulation of Cardiovascular Physiology and Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,766,063 | January 1, 2022 | December 31, 2028 | STRAUB, ADAM CARL | reporter.nih.gov |
| HLA Fine Mapping to Elucidate S. aureus Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,757,863 | September 17, 2021 | August 31, 2026 | FOWLER, VANCE G. | reporter.nih.gov |
| Next generation functional genomics of hematology traits | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,755,651 | February 1, 2020 | April 30, 2028 | REINER, ALEXANDER P | reporter.nih.gov |
| Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,743,381 | September 10, 2021 | August 31, 2027 | ZEBRACK, BRADLEY JAY | reporter.nih.gov |
| Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $3,735,563 | August 10, 2023 | July 31, 2028 | ROLLMAN, BRUCE LAWRENCE | reporter.nih.gov |
| Ikaros regulation: study on hemo-lymphopoiesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,733,682 | September 5, 2011 | March 31, 2029 | GEORGOPOULOS, KATIA | reporter.nih.gov |
| Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic | NIH | National Cancer Institute | 2021 to 2025 | $3,727,726 | September 25, 2001 | June 30, 2026 | WEROHA, SARAVUT | reporter.nih.gov |
| Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,710,340 | September 1, 2023 | August 31, 2028 | WEISS, MITCHELL J | reporter.nih.gov |
| Age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin against catheter-associated thrombosis in critically ill children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,703,719 | September 10, 2021 | August 31, 2027 | FAUSTINO, EDWARD VINCENT | reporter.nih.gov |
| Inflammation and thrombosis fuel cardiovascular and pulmonary disease: Focus on the interplay of neutrophil inflammasomes with NETs | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,692,220 | March 15, 2023 | February 28, 2030 | WAGNER, DENISA D | reporter.nih.gov |
| Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $3,687,540 | September 7, 2017 | June 30, 2032 | DIPERSIO, JOHN F. | reporter.nih.gov |
| Molecular Mechanisms of Human Long-lived Plasma Cell Generation in the Bone Marrow and Spleen | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,685,885 | January 21, 2019 | December 31, 2028 | LEE, FRANCES EUN-HYUNG | reporter.nih.gov |
| Yale Cooperative Center of Excellence in Hematology | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $3,674,149 | August 1, 2015 | July 31, 2026 | KRAUSE, DIANE S | reporter.nih.gov |
| Enhancing immune regulation in gene therapy for hemophilia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,664,714 | July 1, 2016 | June 30, 2029 | HERZOG, ROLAND W. | reporter.nih.gov |
| Minocycline as a potential therapy for neuroinflammation and cognitive deficit in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,659,814 | December 15, 2020 | November 30, 2026 | HYACINTH, HYACINTH IDU | reporter.nih.gov |
| Structural Determinants of PIP2 Regulation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,657,236 | April 1, 1998 | May 31, 2028 | LOGOTHETIS, DIOMEDES E. | reporter.nih.gov |
| Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $3,657,208 | March 1, 2020 | February 28, 2026 | SUSSMAN, ELYSE S | reporter.nih.gov |
| Michigan Center for Translational Cancer Proteogenomics | NIH | National Cancer Institute | 2022 to 2025 | $3,656,494 | June 6, 2022 | May 31, 2027 | NESVIZHSKII, ALEXEY I | reporter.nih.gov |
| Contact Pathway Activation on Vascular Devices | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,655,494 | August 1, 2018 | June 30, 2027 | MCCARTY, OWEN J | reporter.nih.gov |
| Nemours NCI Community Oncology Research Program (NCORP) | NIH | National Cancer Institute | 2021 to 2025 | $3,654,103 | June 2, 2025 | July 31, 2026 | CAYWOOD, EMI H | reporter.nih.gov |
| Fosinopril analogs for the treatment of human babesiosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,646,365 | April 21, 2021 | March 31, 2027 | BEN MAMOUN, CHOUKRI | reporter.nih.gov |
| Molecular strategies for early detection and targeting of cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,640,759 | August 12, 2015 | July 31, 2028 | REYA, TANNISHTHA | reporter.nih.gov |
| NGTC - UCL | NIH | National Cancer Institute | 2022 to 2024 | $3,627,871 | June 1, 2024 | May 31, 2025 | PULE, MARTIN | reporter.nih.gov |
| The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (REACT-AF) | NIH | National Heart, Lung, and Blood Institute | 2022 | $3,610,112 | August 25, 2022 | July 31, 2023 | PASSMAN, ROD S | reporter.nih.gov |
| HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,601,018 | April 9, 2021 | March 31, 2027 | HSU, KATHARINE C | reporter.nih.gov |
| Immune Pathophysiology of Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,589,657 | March 1, 2022 | December 31, 2028 | YAZDANBAKHSH, KARINA | reporter.nih.gov |
| Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,588,034 | September 8, 2023 | August 31, 2028 | CHU, CINDY S | reporter.nih.gov |
| Evaluating Resolution Mechanisms for Infectious Inflammation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,584,466 | April 1, 2021 | March 31, 2027 | SERHAN, CHARLES NICHOLAS | reporter.nih.gov |
| Regulation of LPS-responses by ZBP1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,578,088 | September 22, 2021 | June 15, 2026 | POLTORAK, ALEXANDER | reporter.nih.gov |
| 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $3,567,710 | May 15, 2019 | August 31, 2022 | GLADWIN, MARK T | reporter.nih.gov |
| Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $3,557,045 | May 1, 2021 | April 30, 2024 | NIXON, DOUGLAS F | reporter.nih.gov |
| Preventing GVHD by inhibition of alloantigen presentation in the gut | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,543,040 | July 1, 2019 | June 30, 2027 | HILL, GEOFFREY ROGER | reporter.nih.gov |
| Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers | NIH | National Cancer Institute | 2021 to 2024 | $3,536,890 | April 1, 2020 | September 30, 2025 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Targeting the Intestinal Mucosa and Microbiome to Prevent Neonatal Late-onset Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,526,115 | August 1, 2021 | July 31, 2027 | WEAVER, CASEY T | reporter.nih.gov |
| Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,521,872 | August 1, 2024 | July 31, 2029 | BARBIER, MARIETTE | reporter.nih.gov |
| Hematology Training | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,518,531 | July 1, 1975 | June 30, 2030 | ABKOWITZ, JANIS L | reporter.nih.gov |
| I-TRANSFER Improving TRansitions ANd outcomeS oF sEpsis suRvivors | NIH | National Institute of Nursing Research | 2021 to 2025 | $3,506,198 | September 25, 2015 | November 30, 2026 | BOWLES, KATHRYN HELENE | reporter.nih.gov |
| PROMPT BOLUS admin supplement | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $3,504,025 | September 11, 2020 | August 31, 2026 | BALAMUTH, FRANCES B | reporter.nih.gov |
| Structural biology of telomerase and telomeres | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,486,410 | April 1, 2019 | March 31, 2029 | FEIGON, JULI | reporter.nih.gov |
| An expanded national cohort study of transgender people | NIH | National Institute on Aging | 2021 to 2025 | $3,484,289 | September 15, 2021 | May 31, 2027 | GOODMAN, MICHAEL | reporter.nih.gov |
| Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $3,480,276 | August 1, 2025 | July 31, 2029 | LOH, MIGNON LEE-CHEUN | reporter.nih.gov |
| Hematology Clinical Research Training Program | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,477,279 | July 1, 1979 | June 30, 2029 | BRASS, LAWRENCE F | reporter.nih.gov |
| Development of a Clinical Hemoglobin Modulator | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $3,473,811 | June 1, 2020 | May 31, 2024 | PERRINE, SUSAN PARK | reporter.nih.gov |
| Cardiac Imaging of Neuro-Embolic Mechanisms in Atriopathies causing Stroke (CINEMAS) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $3,473,396 | May 1, 2024 | April 30, 2029 | GOLDBERGER, JEFFREY J | reporter.nih.gov |
| Large-scale Implementation of Community Co-led Maternal Sepsis Care Practices to Reduce Morbidity and Mortality from Maternal Infection | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $3,471,058 | September 30, 2021 | June 30, 2027 | ALLEN, TERRENCE KELBURN | reporter.nih.gov |
| Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells | NIH | National Cancer Institute | 2021 to 2025 | $3,469,484 | January 7, 2021 | December 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Randomized trial of viral specific T-cell infusion to prevent viral infection after hematopoietic stem cell transplant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,457,708 | July 1, 2021 | April 30, 2027 | DAVIES, STELLA MARGARET | reporter.nih.gov |
| Molecular prediction of myeloma in African Americans | NIH | National Cancer Institute | 2022 to 2025 | $3,450,221 | September 12, 2022 | August 31, 2027 | MARINAC, CATHERINE | reporter.nih.gov |
| The MYC Transcription Factor Network and the Path to Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,449,610 | September 1, 2018 | August 31, 2025 | EISENMAN, ROBERT NEIL | reporter.nih.gov |
| Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma | NIH | National Cancer Institute | 2023 to 2025 | $3,449,390 | September 18, 2023 | August 31, 2028 | KUHN, PETER | reporter.nih.gov |
| SUPPORT-AF IV | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,411,751 | August 1, 2021 | June 30, 2027 | KAPOOR, ALOK | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Leveraging Digital Health Solutions to Reduce Learning and Functional Disparities in Children with Cancer - Administrative Supplement | NIH | National Cancer Institute | 2022 to 2025 | $3,407,172 | July 5, 2022 | June 30, 2027 | PATEL, SUNITA K | reporter.nih.gov |
| Mechanisms of Immune Dysfunction after Trauma and Surgical Sepsis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,405,189 | June 1, 2018 | May 31, 2028 | BILLIAR, TIMOTHY R | reporter.nih.gov |
| Translation of a personalized, non-invasive smartphone app for hemoglobin monitoring for chronic anemia patients | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,405,136 | January 1, 2018 | November 30, 2026 | TYBURSKI, ERIKA AMY | reporter.nih.gov |
| Stratifying Patient Immune Endotypes in Sepsis (SPIES Study) | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $3,390,895 | September 5, 2020 | June 30, 2026 | MAILE, ROBERT | reporter.nih.gov |
| B cell determinants of EBV latency (supplement) | NIH | National Cancer Institute | 2022 to 2025 | $3,376,443 | September 9, 2022 | August 31, 2027 | CESARMAN, ETHEL | reporter.nih.gov |
| Center for Iron & Heme Disorders at the University of Utah | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,372,814 | August 5, 2016 | July 31, 2028 | BEAUDIN, ANNA E | reporter.nih.gov |
| Regulation of Hemoglobin Switching | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,354,270 | August 5, 2013 | January 31, 2027 | BLOBEL, GERD A | reporter.nih.gov |
| Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,350,719 | December 15, 2020 | November 30, 2025 | SHAH, NEIL P | reporter.nih.gov |
| Neuroinflammatory mechanisms underlying sepsis-induced cognitive dysfunction | NIH | National Institute on Aging | 2022 to 2025 | $3,346,228 | September 15, 2022 | August 31, 2027 | HARRISON, FIONA EDITH | reporter.nih.gov |
| The role of ferroptosis in red cell aging in vivo and in vitro | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,331,010 | August 1, 2019 | April 30, 2028 | D'ALESSANDRO, ANGELO | reporter.nih.gov |
| Enhancing Treg Therapeutic Efficacy in GVHD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,322,892 | April 15, 2014 | March 31, 2027 | BLAZAR, BRUCE R | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Immunobiology of the normal and injured lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,312,758 | January 1, 2022 | December 31, 2028 | LOONEY, MARK ROBERTS | reporter.nih.gov |
| Predictive informatics monitoring in the Neonatal Intensive Care Unit | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,311,236 | July 10, 2014 | April 30, 2027 | FAIRCHILD, KAREN D | reporter.nih.gov |
| Strategy for Improving Stroke Treatment Response (SISTER) Trial | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $3,308,306 | July 1, 2023 | June 30, 2028 | KHATRI, POOJA | reporter.nih.gov |
| Genomics of Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,302,250 | April 1, 2018 | March 31, 2025 | ALDRED, MICHEALA A | reporter.nih.gov |
| Culture and amplification-free bacterial sepsis diagnosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,298,494 | June 9, 2023 | May 31, 2027 | CELEDON, ALFREDO ANDRES | reporter.nih.gov |
| Malaria parasite determinants of host cell tropism | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,286,067 | July 1, 2022 | June 30, 2027 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Decoding innate immune signaling in normal and myelodysplastic hematopoiesis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,283,833 | January 1, 2023 | December 31, 2029 | STARCZYNOWSKI, DANIEL | reporter.nih.gov |
| MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,275,826 | July 1, 2023 | June 30, 2026 | LANDRUM, JILL | reporter.nih.gov |
| Germline and Somatic Genomic Studies in CLL | NIH | National Cancer Institute | 2021 to 2025 | $3,266,846 | July 1, 2021 | September 30, 2026 | SLAGER, SUSAN L | reporter.nih.gov |
| Low-Dose Magneto-Thrombolysis to Expand Stroke Care | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $3,263,292 | July 1, 2023 | June 30, 2026 | CREIGHTON, FRANCIS MILTON | reporter.nih.gov |
| A Phase 1b Study of Inhaled CO for the Treatment of Sepsis-Induced ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $3,249,318 | September 15, 2020 | April 30, 2025 | PLATAKI, MARIA | reporter.nih.gov |
| PET Imaging of Thrombus | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,247,850 | August 1, 2011 | January 31, 2027 | CARAVAN, PETER D | reporter.nih.gov |
| A spatial view of hematopoietic regeneration dynamics in the bone marrow | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $3,245,428 | September 15, 2024 | July 31, 2029 | LU, RONG | reporter.nih.gov |
| SCD REVIVE - Retina to Evaluate Vaso occlusion In the Vasculature of the Eye | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,242,672 | April 10, 2022 | March 31, 2027 | GLASSBERG, JEFFREY AVINS | reporter.nih.gov |
| Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,235,983 | July 1, 2020 | June 30, 2027 | LAROCCA, CECILIA | reporter.nih.gov |
| Mitochondrial dysfunction driven by splicing factor mutations in MDS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,227,502 | September 15, 2025 | August 31, 2029 | KLEIN, PETER S | reporter.nih.gov |
| Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,218,917 | August 15, 2015 | June 30, 2026 | JENQ, ROBERT | reporter.nih.gov |
| The epigenetic regulation of inflammation in tissue repair and vascular disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,217,378 | July 1, 2023 | June 30, 2030 | GALLAGHER, KATHERINE ANN | reporter.nih.gov |
| Complement and thrombosis in HIT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,216,929 | January 1, 2025 | November 30, 2028 | AREPALLY, GOWTHAMI M | reporter.nih.gov |
| Viper Resource Grant at Texas A&M University-Kingsville | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $3,214,960 | April 15, 2003 | April 30, 2029 | SANCHEZ, ELDA E. | reporter.nih.gov |
| Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $3,211,729 | March 4, 2021 | February 28, 2026 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| Variant Hemoglobin and Cardiorespiratory Regulation in Humans | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,208,613 | January 19, 2018 | November 30, 2024 | JOYNER, MICHAEL J | reporter.nih.gov |
| Pre-malignant mutation landscape and risk factors for progression to hematologic cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,207,103 | April 1, 2021 | March 31, 2027 | DESAI, PINKAL | reporter.nih.gov |
| Socio-environmental context in monoclonal gammopathy of undetermined significance (MGUS) | NIH | National Cancer Institute | 2021 to 2025 | $3,206,176 | June 1, 2021 | May 31, 2027 | BERTRAND, KIMBERLY A. | reporter.nih.gov |
| Outcomes for CLL patients treated with novel therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,205,518 | September 15, 2021 | August 31, 2026 | KAY, NEIL E | reporter.nih.gov |
| Defining human and mouse non-canonical inflammasome responses to LPS | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,204,624 | July 24, 2025 | June 30, 2029 | SHIN, SUNNY | reporter.nih.gov |
| Novel Molecular Biomarkers of Bone Microarchitecture | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,202,138 | September 30, 1991 | March 31, 2027 | KIEL, DOUGLAS P. | reporter.nih.gov |
| Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias | NIH | National Cancer Institute | 2022 to 2025 | $3,200,543 | May 1, 2022 | April 30, 2027 | JIN, JIAN | reporter.nih.gov |
| Pacritinib in rel/refr T-cell lymphomas | NIH | National Cancer Institute | 2021 to 2025 | $3,194,893 | September 1, 2021 | August 31, 2027 | WILCOX, RYAN A | reporter.nih.gov |
| Clonal Hematopoeisis of Indeterminate Potential and Risk of Autopsy-defined Sudden Cardiac Death | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,193,873 | December 1, 2021 | November 30, 2026 | TSENG, ZIAN H | reporter.nih.gov |
| Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,193,450 | September 10, 2021 | August 31, 2026 | ATAGA, KENNETH I | reporter.nih.gov |
| ECMO without Anticoagulation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,193,154 | September 1, 2021 | June 30, 2025 | ROJAS-PENA, ALVARO | reporter.nih.gov |
| Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers | NIH | National Cancer Institute | 2021 to 2024 | $3,192,137 | April 1, 2020 | March 31, 2026 | ARMENIAN, SARO | reporter.nih.gov |
| Hematopoietic Stem Cell And Cord Blood Transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,169,146 | September 30, 2005 | May 31, 2030 | PETERSDORF, EFFIE W | reporter.nih.gov |
| Comparative modeling of multiple myeloma across myeloma continuum: prevention, treatment, and health drivers | NIH | National Cancer Institute | 2021 to 2025 | $3,165,787 | September 20, 2021 | August 31, 2026 | CHANG, SU-HSIN | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| Endothelial Cell to Mesenchymal Cell Transitions Play a Critical Biological Sex- and Aging-Dependent Role in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous Cap | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,155,829 | January 1, 2022 | December 31, 2025 | OWENS, GARY K | reporter.nih.gov |
| Immunomodulation by splenic megakaryocytes and platelets in sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,151,437 | June 7, 2022 | May 31, 2027 | LOONEY, MARK ROBERTS | reporter.nih.gov |
| Biochemistry and Pathophysiology of Factor XI and Contact Activation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,144,201 | January 16, 2018 | June 30, 2025 | GAILANI, DAVID | reporter.nih.gov |
| Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | NIH | National Cancer Institute | 2021 to 2025 | $3,143,480 | April 1, 2021 | March 31, 2027 | BROWN, JENNIFER R | reporter.nih.gov |
| Lab Research Training in Pediatric Oncology-Hematology | NIH | National Cancer Institute | 2021 to 2025 | $3,128,223 | September 30, 1993 | July 31, 2028 | FRIEDMAN, ALAN D | reporter.nih.gov |
| Optimizing anti-microbial immunity by targeting Sts-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,125,627 | July 23, 2025 | June 30, 2029 | CARPINO, NICHOLAS A | reporter.nih.gov |
| Parametric Response Mapping (PRM) for the detection of chronic lung injury in hematopoietic cell transplant recipients | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,121,383 | August 15, 2022 | July 31, 2026 | YANIK, GREGORY A | reporter.nih.gov |
| Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation | NIH | National Cancer Institute | 2021 to 2025 | $3,120,296 | August 1, 2021 | July 31, 2027 | HAHN, THERESA E | reporter.nih.gov |
| Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation. | NIH | National Cancer Institute | 2021 to 2025 | $3,119,515 | July 1, 2020 | June 30, 2027 | VINCENT, BENJAMIN G | reporter.nih.gov |
| Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,116,857 | May 1, 2016 | October 31, 2026 | AYALA, ALFRED | reporter.nih.gov |
| Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL) | NIH | National Cancer Institute | 2021 to 2025 | $3,113,868 | July 1, 2021 | June 30, 2027 | CALABRETTA, BRUNO | reporter.nih.gov |
| TYK2 Fusions in Lymphoma | NIH | National Cancer Institute | 2025 | $3,111,184 | September 1, 2025 | August 31, 2029 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Iron Deficiency and Brain Development in Youth with Internalizing Disorders | NIH | National Institute of Mental Health | 2021 to 2024 | $3,111,063 | September 17, 2020 | August 31, 2025 | CALARGE, CHADI A. | reporter.nih.gov |
| Autonomous Grippers in the Gastrointestinal Tract | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $3,105,853 | September 26, 2014 | June 30, 2026 | SELARU, FLORIN | reporter.nih.gov |
| Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease | NIH | National Cancer Institute | 2023 to 2025 | $3,096,663 | September 1, 2023 | August 31, 2028 | MARTINEZ, OLIVIA M | reporter.nih.gov |
| Leveraging canine spontaneous cancer to optimize the power of blood biopsy | NIH | National Cancer Institute | 2021 to 2025 | $3,095,555 | June 7, 2021 | May 31, 2027 | KARLSSON, ELINOR | reporter.nih.gov |
| UM Calabresi Clinical Oncology Research Career Development Award | NIH | National Cancer Institute | 2021 to 2025 | $3,093,598 | June 29, 2018 | August 31, 2028 | POLLACK, ALAN | reporter.nih.gov |
| The Impact of Cerebral Metabolic Stress on the Development of the Structural and Functional Connectome in Pediatric Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,089,102 | April 5, 2021 | March 31, 2027 | FIELDS, MELANIE ERIN | reporter.nih.gov |
| Development of a Universal Bi-ventricular Replacement System for the Failing Heart | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,085,748 | May 1, 2021 | April 30, 2026 | CYSYK, JOSHUA P | reporter.nih.gov |
| Privileged and primitive hematopoietic stem cells, niches, and regulatory T cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,081,005 | December 1, 2021 | November 30, 2025 | FUJISAKI, JOJI | reporter.nih.gov |
| Role of the Cell Death Machinery in a Somatic Autoinflammatory Syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,066,524 | August 21, 2025 | July 31, 2029 | GITLIN, ALEXANDER | reporter.nih.gov |
| Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $3,058,782 | September 23, 2019 | June 30, 2026 | KORCZAK, BOZENA | reporter.nih.gov |
| Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $3,056,754 | April 1, 2021 | March 31, 2027 | DAVIS, KARA LYNN | reporter.nih.gov |
| Direct-from-specimen identification of pathogens common in endocarditis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,051,028 | January 4, 2018 | December 31, 2026 | SINGER, ALON | reporter.nih.gov |
| Direct detection and identification of antimicrobial resistance genes in bloodstream infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,050,000 | August 9, 2022 | July 31, 2025 | SINGER, ALON | reporter.nih.gov |
| Beta-2 adrenergic signaling in immune homeostasis and reconstitution | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,048,780 | April 15, 2022 | March 31, 2027 | CAO, XUEFANG | reporter.nih.gov |
| Structure and functional mechanisms of molecular chaperones and protein kinases | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,046,637 | May 1, 2017 | January 31, 2028 | KALODIMOS, CHARALAMPOS | reporter.nih.gov |
| ErythroMer: Nanoscale BioSynthetic Red Cell Substitute | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,043,060 | May 11, 2017 | May 31, 2027 | ALP, ESMA | reporter.nih.gov |
| Platelet Integrin AlphaIIbBeta3 Structure, Activation, and Ligand Binding: Fibrinogen, Fibrin, D-dimer, and von Willebrand Factor | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,038,586 | September 1, 1976 | May 5, 2026 | COLLER, BARRY | reporter.nih.gov |
| Training Program in Molecular Hematology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,036,856 | August 1, 2013 | July 31, 2029 | BERLINER, NANCY | reporter.nih.gov |
| CHOICES for Sickle Cell Reproductive Health: RCT of a Preconception Intervention Model for a Single Gene Disorder | NIH | National Human Genome Research Institute | 2021 to 2024 | $3,034,701 | September 1, 2021 | June 30, 2026 | WILKIE, DIANA J | reporter.nih.gov |
| Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $3,033,785 | June 1, 2020 | May 31, 2025 | LEBENSBURGER, JEFFREY D | reporter.nih.gov |
| Diagnostic tool for assessment and tracking of microbial load in bloodstream infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,031,639 | June 23, 2023 | May 31, 2027 | SINGER, ALON | reporter.nih.gov |
| Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,027,494 | July 1, 2023 | June 30, 2028 | NIZET, VICTOR | reporter.nih.gov |
| Dynamic 3D chromatin remodeling in acute leukemia - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $3,027,488 | April 1, 2021 | June 30, 2026 | TSIRIGOS, ARISTOTELIS | reporter.nih.gov |
| Host Directed Orynotide for MDR Gram Negative Bacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,025,760 | July 21, 2023 | June 30, 2028 | SCHAAL, JUSTIN BLAINE | reporter.nih.gov |
| New York Consortium for Interdisciplinary Training in Kidney, Urological and Hematological Research (NYC Train KUHR) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,023,587 | September 15, 2022 | June 30, 2027 | KASKEL, FREDERICK JEFFREY | reporter.nih.gov |
| Functional Lung Imaging Using a Single kV CT Acquisition | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,023,272 | July 1, 2021 | June 30, 2026 | CHEN, GUANG-HONG | reporter.nih.gov |
| MAb Passive Vaccination against Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,021,383 | September 25, 2017 | August 31, 2027 | SPELLBERG, BRAD J | reporter.nih.gov |
| Adaptation of vancomycin-resistant enterococci during bloodstream infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,020,097 | June 3, 2022 | May 31, 2027 | VAN TYNE, DARIA N | reporter.nih.gov |
| Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV | NIH | National Cancer Institute | 2022 to 2025 | $3,019,287 | September 12, 2022 | August 31, 2027 | BHADURI-MCINTOSH, SUMITA | reporter.nih.gov |
| Epigenetic contribution to the excess risk of MGUS in African Americans | NIH | National Cancer Institute | 2021 to 2025 | $3,018,736 | May 13, 2021 | April 30, 2027 | BROWN, ELIZABETH E | reporter.nih.gov |
| Therapeutic Implications of Molecular Defects in Bone Marrow Failure | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $3,016,565 | January 12, 2017 | December 31, 2023 | MACIEJEWSKI, JAROSLAW P. | reporter.nih.gov |
| Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $3,015,518 | September 21, 2017 | August 31, 2024 | WEISSMAN, IRVING L. | reporter.nih.gov |
| Protein-RNA interactions in cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,012,718 | August 1, 2021 | July 31, 2027 | SANFORD, JEREMY ROBERT | reporter.nih.gov |
| Cbfb in RORgt-regulated T cell function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,010,210 | May 1, 2014 | May 31, 2029 | SUN, ZUOMING | reporter.nih.gov |
| Non-Clinical Pharmacology of CX-01 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,007,043 | June 1, 2014 | January 31, 2027 | VID, GALINA | reporter.nih.gov |
| Mechanisms of Radiation-Induced Innate Immune Dysfunction and Its Countermeasures | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,005,089 | July 21, 2022 | May 31, 2027 | WANG, PING | reporter.nih.gov |
| Characterization of an isoform specific anticoagulant function of TFPI-alpha | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,004,684 | August 1, 2002 | June 30, 2028 | MAST, ALAN E | reporter.nih.gov |
| Massively Multiplexed dsDNA Invasion Arrays | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | April 14, 2021 | March 31, 2025 | SINGER, ALON | reporter.nih.gov |
| An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | July 1, 2016 | March 31, 2025 | SINGER, ALON | reporter.nih.gov |
| Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,000,000 | March 3, 2022 | February 28, 2026 | SINGER, ALON | reporter.nih.gov |
| Highly Multiplexed Single Molecule Tethering | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,694 | August 17, 2023 | July 31, 2027 | CELEDON, ALFREDO ANDRES | reporter.nih.gov |
| Development of a Dual-Targeting ClpP Activating Antibiotic | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,619 | September 1, 2023 | August 31, 2026 | LAFLEUR, MICHAEL | reporter.nih.gov |
| HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,999,194 | April 7, 2016 | February 28, 2027 | GOMPERTS, EDWARD | reporter.nih.gov |
| Nociceptive Mechanisms Underlying Sickle Cell Pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,998,866 | September 30, 2009 | December 31, 2028 | STUCKY, CHERYL LOUISE | reporter.nih.gov |
| FXIIIA production by mast cells for innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,997,988 | April 24, 2020 | March 31, 2025 | PILIPONSKY, ADRIAN M | reporter.nih.gov |
| Transcriptional Networks Controlling Erythroid Differentiation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,997,877 | March 1, 1999 | March 31, 2027 | BLOBEL, GERD A | reporter.nih.gov |
| Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,997,234 | June 20, 2023 | May 31, 2027 | SINGER, ALON | reporter.nih.gov |
| Antithrombotic Protein C Activator for Hemodialysis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,997,175 | May 15, 2019 | April 30, 2025 | TUCKER, ERIK IAN | reporter.nih.gov |
| Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,996,021 | June 1, 2011 | January 31, 2027 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Targeting MicroRNAs to Eradicate Leukemia Stem Cells | NIH | National Cancer Institute | 2021 to 2025 | $2,990,517 | August 1, 2017 | July 31, 2027 | KUO, YA-HUEI | reporter.nih.gov |
| The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,990,146 | March 5, 2022 | February 28, 2026 | BOUCHER, RICHARD CHARLES | reporter.nih.gov |
| Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell | NIH | National Cancer Institute | 2022 to 2025 | $2,988,832 | September 12, 2022 | August 31, 2027 | LIU, SHUJUN | reporter.nih.gov |
| Mechanistic role of membrane pore formation in lung-endothelial barrier failure due to blood-borne pathogens. | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,988,753 | June 1, 1985 | July 31, 2027 | BHATTACHARYA, JAHAR | reporter.nih.gov |
| Adhesion GPCR regulation of acute myeloid leukemia stem cells - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $2,988,590 | March 1, 2021 | February 28, 2026 | PARK, CHRISTOPHER Y | reporter.nih.gov |
| Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms | NIH | National Cancer Institute | 2021 to 2025 | $2,986,870 | July 1, 2021 | June 30, 2026 | MACIEJEWSKI, JAROSLAW P. | reporter.nih.gov |
| Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,986,386 | September 1, 2018 | February 28, 2026 | GALEN, PETER | reporter.nih.gov |
| Stem Cell and Transplantation Biology | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,984,057 | August 1, 2015 | July 31, 2028 | STIREWALT, DEREK L | reporter.nih.gov |
| Direct from blood identification of bloodstream infections in newborns | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,981,785 | August 1, 2022 | July 31, 2025 | SINGER, ALON | reporter.nih.gov |
| Safety and Tolerability Studies for an Anti-Fibrin P2 Monoclonal Antibody for the Treatment of Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2023 | $2,970,786 | September 30, 2021 | August 31, 2024 | KANTOR, AARON B | reporter.nih.gov |
| Effectiveness and Safety of Transcatheter Left Atrial Appendage Occlusion vs. Anticoagulation in Older Adults with Atrial Fibrillation and Alzheimer's Disease and Related dementias | NIH | National Institute on Aging | 2022 to 2025 | $2,962,676 | August 1, 2022 | April 30, 2027 | LIN, JOSHUA K | reporter.nih.gov |
| Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,961,810 | July 1, 2021 | June 30, 2026 | YANG, JUN J. | reporter.nih.gov |
| Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | NIH | National Cancer Institute | 2022 to 2025 | $2,958,176 | December 15, 2021 | November 30, 2026 | BOUCHARD, ELIZABETH | reporter.nih.gov |
| MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,957,506 | August 20, 2020 | July 31, 2026 | VASU, SUMITHIRA | reporter.nih.gov |
| Discovery and Characterization of Genetic Risk Loci in Sjogren's Syndrome | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,957,132 | September 7, 2020 | August 31, 2025 | LESSARD, CHRISTOPHER J | reporter.nih.gov |
| Brain signature of SARS-CoV-2 Infection and its impact on long-term cognitive functioning in older adults | NIH | National Institute on Aging | 2022 to 2025 | $2,954,828 | July 1, 2022 | June 30, 2027 | SCHIFITTO, GIOVANNI | reporter.nih.gov |
| Immune tolerance induction by AAV-FVIII gene therapy for canine hemophilia A with inhibitors | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,952,138 | September 1, 2021 | June 30, 2026 | SAMELSON-JONES, BEN J | reporter.nih.gov |
| Functions and mechanisms of transcriptional coactivator OCA-B in B cell development and lymphomagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,950,108 | December 12, 2019 | November 30, 2025 | ROEDER, ROBERT G | reporter.nih.gov |
| Control of Type I Interferon Production in Response to Candida albicans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,947,724 | April 10, 2020 | March 31, 2026 | VYAS, JATIN M | reporter.nih.gov |
| Defining the cause and consequence of aging-specific platelet specification from hematopoietic stem cells | NIH | National Institute on Aging | 2021 to 2025 | $2,943,876 | September 15, 2019 | May 31, 2029 | FORSBERG, CAMILLA | reporter.nih.gov |
| Transfusion and Organ Dysfunction in Pediatric Septic Shock (TROPICS) study | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,942,460 | March 20, 2022 | February 28, 2027 | MUSZYNSKI, JENNIFER | reporter.nih.gov |
| Epidemiology of Venous Thrombosis and Pulmonary Embolism | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,941,493 | February 1, 1998 | February 28, 2026 | TANG, WEIHONG | reporter.nih.gov |
| Clonal hematopoiesis, inflammasomes and atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,941,081 | February 15, 2021 | January 31, 2029 | TALL, ALAN RICHARD | reporter.nih.gov |
| Modeling Multi-Source Data in Hodgkin Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,935,832 | March 1, 2022 | February 28, 2027 | PARSONS, SUSAN KENYON | reporter.nih.gov |
| Regulation of hematopoiesis by ribosomal protein paralogs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,934,669 | February 1, 2025 | January 31, 2030 | WIEST, DAVID L. | reporter.nih.gov |
| Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,933,453 | July 15, 2022 | April 30, 2027 | HOWELL, REBECCA MAUREEN | reporter.nih.gov |
| Backtracking Leukemia-Typical Somatic Alterations in Cord Blood at Single-cell Resolution | NIH | National Cancer Institute | 2021 to 2025 | $2,927,357 | August 1, 2021 | July 31, 2026 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Molecular Mechanisms of Drug Resistance in Primary Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,926,627 | January 1, 2018 | November 30, 2025 | MELLINGHOFF, INGO K | reporter.nih.gov |
| 2/2 Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,922,467 | May 15, 2024 | April 30, 2031 | DAS, ABHIK | reporter.nih.gov |
| Mechanisms of epitranscriptomic regulation in cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,917,446 | September 10, 2014 | August 31, 2029 | JAFFREY, SAMIE R | reporter.nih.gov |
| Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | NIH | National Cancer Institute | 2022 to 2025 | $2,917,317 | December 9, 2021 | November 30, 2026 | KENDERIAN, SAAD J. | reporter.nih.gov |
| Modeling myelodysplasia | NIH | National Cancer Institute | 2021 to 2025 | $2,916,597 | January 1, 2021 | December 31, 2026 | GRIMES, H. LEIGHTON | reporter.nih.gov |
| Changing Cultures in Sepsis: Rapid single-cell pathogen identification and antibiotic susceptibility testing directly from whole blood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,910,960 | June 15, 2020 | May 31, 2026 | YANG, SAMUEL | reporter.nih.gov |
| Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,908,098 | February 1, 2018 | March 31, 2025 | PAMULA, VAMSEE K. | reporter.nih.gov |
| Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation | NIH | National Institute on Aging | 2021 to 2025 | $2,907,195 | September 15, 2021 | June 30, 2027 | TROWBRIDGE, JENNIFER JEAN | reporter.nih.gov |
| An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,903,398 | June 15, 2019 | June 30, 2027 | JONES, CURTIS | reporter.nih.gov |
| Information flow and state transitions at the system and multi-dimensional scales in leukemia progression | NIH | National Cancer Institute | 2021 to 2024 | $2,901,922 | May 1, 2020 | April 30, 2025 | ROCKNE, RUSSELL CHRISTIAN | reporter.nih.gov |
| Personalized Adoptive T-cell Therapy for AML | NIH | National Cancer Institute | 2021 to 2025 | $2,900,444 | July 1, 2021 | December 31, 2026 | AVIGAN, DAVID E. | reporter.nih.gov |
| The DNA damage response of fast-cycling erythroblasts | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,899,464 | August 25, 2021 | October 31, 2026 | SOCOLOVSKY, MERAV | reporter.nih.gov |
| Roles of Neogenin and Matriptase-2 in Iron Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,896,213 | February 1, 2015 | July 31, 2028 | ZHANG, AN-SHENG | reporter.nih.gov |
| The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,895,508 | December 12, 2019 | January 31, 2025 | SAMAYOA REYES, GABRIELA M | reporter.nih.gov |
| PreQuine Platform. A novel point of care device for the diagnosis andmonitoring of Glucose-6-Phosphate Dehydrogenase (G6PD) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,893,164 | February 8, 2017 | August 31, 2025 | HARPER, ROBERT | reporter.nih.gov |
| Training Core | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $2,893,038 | September 1, 2024 | May 31, 2029 | GREKA, ANNA | reporter.nih.gov |
| Function and Evolutionary Origins of the RAG Endonuclease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,890,366 | September 11, 2018 | July 31, 2028 | SCHATZ, DAVID G. | reporter.nih.gov |
| Role of Complement Activation in Severe COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,886,906 | August 20, 2022 | July 31, 2026 | QIN, XUEBIN | reporter.nih.gov |
| A Mobile Relational Agent to Enhance Atrial Fibrillation Self-care | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,884,620 | April 27, 2020 | March 31, 2025 | MAGNANI, JARED W. | reporter.nih.gov |
| UNC Oncology K12 | NIH | National Cancer Institute | 2021 to 2025 | $2,880,051 | September 17, 2007 | June 30, 2029 | KIM, WILLIAM Y. | reporter.nih.gov |
| Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices | NIH | National Cancer Institute | 2021 to 2025 | $2,877,928 | March 1, 2021 | February 28, 2026 | PECOT, CHAD V | reporter.nih.gov |
| The Biogenesis of Platelet-Derived Extracellular Vesicles and their Impact on Megakaryocyte Maturation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,874,833 | April 20, 2021 | March 31, 2027 | MACHLUS, KELLIE RAE | reporter.nih.gov |
| Calpain/talin/MLCP axis in pulmonary endothelial barrier regulation | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,873,437 | September 1, 2022 | August 31, 2026 | VERIN, ALEXANDER D | reporter.nih.gov |
| Metabolic control of normal and malignant hematopoiesis | NIH | National Cancer Institute | 2021 to 2025 | $2,869,404 | September 1, 2020 | May 31, 2027 | INTLEKOFER, ANDREW MICHAEL | reporter.nih.gov |
| Assessment of Implementation Methods in Sepsis and Respiratory Failure | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,868,952 | July 15, 2022 | June 30, 2027 | LEVY, MITCHELL M | reporter.nih.gov |
| Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,867,908 | June 1, 2020 | May 31, 2026 | WALLER, EDMUND K | reporter.nih.gov |
| Clonal hematopoiesis in humans: determinants of development and progression | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,867,247 | July 19, 2019 | March 31, 2025 | BALLANTYNE, CHRISTIE MITCHELL | reporter.nih.gov |
| Mechanisms of STING-associated autoinflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,866,706 | March 1, 2019 | January 31, 2029 | MINER, JONATHAN J | reporter.nih.gov |
| Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescentsand Young Adults with Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,864,905 | March 24, 2021 | February 28, 2027 | WOLFSON, JULIE ANNA | reporter.nih.gov |
| Uncovering mechanisms of protection from Alzheimer's disease in CHIP using human cohorts and biosamples | NIH | National Institute on Aging | 2024 to 2025 | $2,857,034 | September 17, 2024 | May 31, 2029 | JAISWAL, SIDDHARTHA | reporter.nih.gov |
| Molecular regulation of native hematopoiesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,856,222 | February 15, 2016 | December 31, 2025 | CAMARGO, FERNANDO | reporter.nih.gov |
| Translational Control of Megakaryocyte and Platelet Gene Expression in Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,853,399 | January 1, 2019 | December 31, 2025 | WEYRICH, ANDREW S | reporter.nih.gov |
| Development of PTLS-209 for treatment for giardiasis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,849,878 | July 12, 2022 | June 30, 2027 | PADIA, JANAK K | reporter.nih.gov |
| Wnt signaling in hematopoietic development | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,849,578 | January 1, 2017 | June 30, 2025 | WILLERT, KARL H | reporter.nih.gov |
| A Severe Hemophilia A Intergenerational Cohort Research Program for the Study of Factor VIII Immunogenicity | NIH | National Heart, Lung, and Blood Institute | 2025 | $2,849,004 | September 21, 2022 | August 31, 2029 | JOHNSEN, JILL MARIE | reporter.nih.gov |
| SBIR Phase II: Novel Hyaluronan Enhanced Polymeric Trans-Catheter Aortic Valve | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,844,232 | August 17, 2021 | June 30, 2027 | TOMBA, TODD CHARLES | reporter.nih.gov |
| Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | NIH | National Cancer Institute | 2021 to 2025 | $2,839,105 | April 1, 2021 | March 31, 2027 | VINCI, CHRISTINE | reporter.nih.gov |
| Biomarkers of ischemic brain injury in adults with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,834,684 | February 15, 2022 | January 31, 2027 | JORDAN, LORI CHAFFIN | reporter.nih.gov |
| Renal Metabolism in AKI | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,833,514 | September 15, 2025 | September 14, 2029 | SINGH, PRABHLEEN | reporter.nih.gov |
| Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,831,392 | September 28, 2012 | April 30, 2027 | FLEMING, ROBERT E | reporter.nih.gov |
| Pathobiology of VPS45 severe congenital neutropenia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,830,535 | February 7, 2020 | January 31, 2026 | NEWBURGER, PETER E | reporter.nih.gov |
| Investigating Syndecan-1 in Hepcidin Regulation and Iron Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,828,600 | February 1, 2021 | April 9, 2026 | GORDTS, PHILIP | reporter.nih.gov |
| Impact of Genetic susceptibility along the continuum from MGUS to MM | NIH | National Cancer Institute | 2022 to 2025 | $2,826,486 | May 1, 2022 | April 30, 2027 | VACHON, CELINE M | reporter.nih.gov |
| Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,824,730 | May 1, 2021 | April 30, 2026 | CONNOR, JOHN H | reporter.nih.gov |
| NANOPHOTOSENSITIZERS FOR REGENERATIVE PHOTOTHERAPY | NIH | National Cancer Institute | 2022 to 2025 | $2,822,017 | August 4, 2021 | July 31, 2027 | ACHILEFU, SAMUEL | reporter.nih.gov |
| Developing gene therapy strategies to treat alpha thalassemia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,821,947 | January 1, 2022 | December 31, 2025 | MACKENZIE, TIPPI | reporter.nih.gov |
| Multiscale Model of Thrombosis in Artificial Circulation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,819,437 | February 1, 2009 | April 30, 2026 | ANTAKI, JAMES F. | reporter.nih.gov |
| Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,817,681 | July 5, 2021 | March 31, 2025 | JEONG, SUN YONG | reporter.nih.gov |
| Production of Cultured Red Blood Cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,816,822 | September 15, 2015 | March 31, 2029 | BOUHASSIRA, ERIC E. | reporter.nih.gov |
| Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,805,290 | August 1, 2021 | July 31, 2025 | SUN, JIANXIN | reporter.nih.gov |
| Cellular and molecular analysis of B lymphocyte development and selection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,800,489 | June 15, 2014 | April 30, 2030 | PEREIRA, JOAO | reporter.nih.gov |
| Characterization of Coagulation Factor-platelet Interactions: Role of FXI | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,797,266 | July 15, 2010 | April 30, 2028 | MCCARTY, OWEN J | reporter.nih.gov |
| Hepatic gene transfer for the treatment of hemophilia B and other genetic diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,797,035 | September 1, 2000 | December 31, 2027 | KAY, MARK A | reporter.nih.gov |
| Novel Approaches to Maintaining Organ Function in Sepsis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,796,919 | June 1, 2016 | June 30, 2027 | WANG, PING | reporter.nih.gov |
| TFPI, Protein S, and Plasma FIXa in Hormone-Induced Hypercoagulability | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,796,684 | August 1, 2021 | July 31, 2025 | MAST, ALAN E | reporter.nih.gov |
| 2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,796,573 | September 20, 2020 | August 31, 2026 | CASPER, THERON C | reporter.nih.gov |
| Functional Characterization of Children with Chronic Venous Thromboembolic Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,795,607 | September 1, 2021 | June 30, 2026 | ZIA, AYESHA | reporter.nih.gov |
| Dissecting the molecular mechanisms of lung injury during mechanical ventilation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,791,533 | February 15, 2021 | January 31, 2027 | ENGLERT, JOSHUA A | reporter.nih.gov |
| EnCoRe MOMS: Engaging Communities to Reduce Morbidity from Maternal Sepsis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,790,846 | September 21, 2022 | September 20, 2026 | GOFFMAN, DENA | reporter.nih.gov |
| Vertically transferred antibodies protect babies from Escherichia coli infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,790,604 | September 11, 2025 | August 31, 2029 | WAY, SING SING | reporter.nih.gov |
| Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,785,889 | February 1, 2020 | January 31, 2026 | ARMENIAN, SARO | reporter.nih.gov |
| Severe Maternal Morbidity: An Investigation of Joint Impacts of Risk Factors and Cumulative Risks Across Successive Pregnancies | NIH | National Institute of Nursing Research | 2021 to 2025 | $2,779,271 | January 19, 2018 | March 31, 2028 | CARMICHAEL, SUZAN L | reporter.nih.gov |
| Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,777,901 | August 15, 2016 | June 30, 2026 | MIAO, CAROL H | reporter.nih.gov |
| Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,776,588 | September 16, 2021 | August 31, 2026 | YU, JIYANG | reporter.nih.gov |
| Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,773,800 | February 1, 2006 | June 30, 2027 | IBRAHIM, ASHRAF S. | reporter.nih.gov |
| Treatment of chronic venous thrombosis with histotripsy and thrombolytics | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,773,786 | December 15, 2017 | July 31, 2028 | BADER, KENNETH B. | reporter.nih.gov |
| Sickle Pan-African Research Consortium Clinical Coordinating Center (SPARCO Center) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,772,178 | April 1, 2017 | April 30, 2027 | MAKANI, JULIE | reporter.nih.gov |
| A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity | NIH | National Cancer Institute | 2022 to 2025 | $2,770,577 | February 24, 2022 | January 31, 2027 | DIEFENBACH, CATHERINE SIBYL | reporter.nih.gov |
| Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,768,708 | September 12, 2014 | June 30, 2027 | CRANE, HEIDI M. | reporter.nih.gov |
| Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | NIH | National Cancer Institute | 2022 to 2025 | $2,766,745 | July 1, 2022 | June 30, 2027 | JIM, HEATHER S.L. | reporter.nih.gov |
| Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,766,158 | September 1, 2023 | August 31, 2028 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Glycemic Observation Using A1C for Gestational Diabetes Diagnosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,763,366 | June 15, 2022 | May 31, 2027 | POWE, CAMILLE ELISE | reporter.nih.gov |
| Gut Flora metabolism of dietary carnitine and cardiovascular disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,763,113 | August 1, 2010 | April 30, 2026 | HAZEN, STANLEY L | reporter.nih.gov |
| Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,758,516 | July 1, 2022 | June 30, 2027 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| Regulation of anti-tumor immunity by HDAC11 | NIH | National Cancer Institute | 2021 to 2024 | $2,757,378 | June 1, 2020 | May 31, 2026 | SETO, EDWARD | reporter.nih.gov |
| Thiol Isomerases in Hemostasis and Thrombosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,752,656 | February 1, 2017 | April 30, 2024 | FLAUMENHAFT, ROBERT C | reporter.nih.gov |
| Rhesus HHV-8 homologue in AIDS-related malignancies | NIH | National Cancer Institute | 2021 to 2024 | $2,752,636 | July 1, 1997 | July 31, 2025 | WONG, SCOTT W | reporter.nih.gov |
| Continuous Therapeutic Drug Monitoring of Antibiotics in CRRT | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,752,374 | February 1, 2021 | January 31, 2026 | MOHAN, SUMIT | reporter.nih.gov |
| EXERCISE OPTION PERIOD 2 FOR BPA ORDER TITLED "CONTENT DEVELOPMENT AND GRAPHIC/MEDICAL ARTS, IMAGING, AND BRAND MANAGEMENT" AGAINST THE NHLBI OSPEEC B | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $2,748,495 | September 15, 2020 | March 14, 2024 | PISONE, THUY | reporter.nih.gov |
| Modulate Cullin-RING E3 ubiquitin ligases by small molecule agents | NIH | National Cancer Institute | 2021 to 2024 | $2,747,835 | July 1, 2020 | June 30, 2025 | PAN, ZHEN-QIANG | reporter.nih.gov |
| Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,746,146 | May 5, 2014 | February 28, 2026 | NEKHAI, SERGEI | reporter.nih.gov |
| In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,743,808 | January 10, 2023 | December 31, 2027 | LIEBER, ANDRE MICHAEL | reporter.nih.gov |
| Clinical and Molecular Heterogeneity in the Myelodysplastic Syndromes | NIH | National Cancer Institute | 2021 to 2024 | $2,742,067 | April 1, 2020 | March 31, 2025 | PARK, CHRISTOPHER Y | reporter.nih.gov |
| Benzodiazepine mediated mechanisms of transcriptional semi-quiescence in discrete myeloid populations | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,741,871 | September 15, 2022 | June 30, 2027 | GASKILL, PETER JESSE | reporter.nih.gov |
| Complement C1q and sepsis associated fatalities | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,739,876 | July 1, 2022 | June 30, 2027 | KIM, MINSOO | reporter.nih.gov |
| Modeling informatics data to track maternal risk and care quality | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,737,921 | September 8, 2022 | August 31, 2027 | FRIEDMAN, ALEXANDER M | reporter.nih.gov |
| 3D Models of the Blood-Brain Barrier for Studying Trauma-Induced Cerebral and Systemic Injuries | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,735,039 | September 3, 2020 | August 31, 2025 | ZHENG, YING | reporter.nih.gov |
| Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,731,934 | September 20, 2021 | August 31, 2026 | SEWARD, KIRK | reporter.nih.gov |
| Mechanism and Regulation of V(D)J Recombination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,727,361 | April 1, 1992 | July 31, 2027 | SCHATZ, DAVID G. | reporter.nih.gov |
| Conformal Total Body and Marrow Irradiation for Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,727,228 | September 13, 2011 | December 31, 2025 | HUI, SUSANTA K | reporter.nih.gov |
| An ABO Blood Type Defined ARDS Endotype in Sepsis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,726,654 | September 21, 2021 | August 31, 2026 | REILLY, JOHN PATRICK | reporter.nih.gov |
| Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,726,409 | February 15, 2022 | January 31, 2026 | LANDAU, DAN | reporter.nih.gov |
| Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | NIH | National Cancer Institute | 2021 to 2024 | $2,726,050 | September 1, 2020 | May 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Hemophilia Point-of-Care Monitoring Device and App | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,724,565 | September 10, 2020 | February 28, 2027 | CHAN, EUGENE YAN-HO | reporter.nih.gov |
| Targeted degradation of RNAs by using small molecules | NIH | National Cancer Institute | 2022 to 2025 | $2,723,786 | April 1, 2020 | March 31, 2030 | DISNEY, MATTHEW D | reporter.nih.gov |
| Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,723,368 | February 9, 2021 | March 31, 2027 | CARRASCO, RUBEN D | reporter.nih.gov |
| Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies | NIH | National Cancer Institute | 2021 to 2024 | $2,720,622 | July 1, 2020 | June 30, 2025 | WANG, JIN | reporter.nih.gov |
| Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,718,598 | May 1, 2018 | April 30, 2028 | HOTCHKISS, RICHARD SAMUEL | reporter.nih.gov |
| Novel Approaches to CD33-Directed Radioimmunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,717,065 | December 1, 2024 | November 30, 2026 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| Patient-specific thrombosis risk in atrial fibrillation by 4D CT imaging of atrial kinetics combined with computational fluid dynamics | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,715,396 | September 1, 2021 | August 31, 2025 | KAHN, ANDREW | reporter.nih.gov |
| BAF complex deregulation in lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,711,912 | August 2, 2022 | July 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Lcn10 in Sepsis-Induced Vascular Leakage and Heart Failure | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,711,450 | December 1, 2021 | November 30, 2026 | FAN, GUO-CHANG | reporter.nih.gov |
| The paradoxical response to iron in pulmonary hypertension of sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,709,179 | February 1, 2022 | January 31, 2027 | IRWIN, DAVID CHARLES | reporter.nih.gov |
| Deep South KUH Premier Research - Interdisciplinary Mentored Education (PRIME) Training Core | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,708,913 | September 1, 2023 | June 30, 2028 | POLLOCK, DAVID M | reporter.nih.gov |
| The Role of Erythroferrone in Regulating Bone Metabolism in Beta-Thalassemia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,707,032 | September 1, 2015 | January 31, 2026 | GINZBURG, YELENA | reporter.nih.gov |
| Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans | NIH | National Cancer Institute | 2021 to 2025 | $2,706,923 | May 1, 2021 | April 30, 2027 | ROSEN, STEVEN TERRY | reporter.nih.gov |
| Towards optimizing diabetes management and diagnosis by personalizing HbA1c targets | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,706,819 | July 1, 2020 | March 31, 2026 | COHEN, ROBERT MAYNARD | reporter.nih.gov |
| Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos | NIH | National Cancer Institute | 2022 to 2025 | $2,704,822 | May 1, 2022 | April 30, 2026 | DE SMITH, ADAM | reporter.nih.gov |
| Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,704,399 | September 15, 2022 | May 31, 2027 | COOK, KEITH E | reporter.nih.gov |
| Mitochondrial Regulation of Hematopoietic Stem Cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,703,143 | January 17, 2017 | December 31, 2025 | SNOECK, HANS-WILLEM E | reporter.nih.gov |
| Clonal Hematopoiesis in the Women's Health Initiative | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,701,565 | July 15, 2019 | March 31, 2028 | REINER, ALEXANDER P | reporter.nih.gov |
| MDS-Associated Spliceosome Mutations Regulate Host Defense | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,696,549 | March 11, 2021 | February 28, 2027 | ALPER, SCOTT | reporter.nih.gov |
| Training Core | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,694,665 | September 15, 2021 | May 31, 2027 | NEMETH, ELIZABETA | reporter.nih.gov |
| Epigenetic Profiling of circulating cell-free DNA for the Monitoring of Graft-Versus-Host Disease after Hematopoietic Cell Transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,694,538 | January 13, 2020 | December 31, 2025 | DE VLAMINCK, IWIJN | reporter.nih.gov |
| Emergency Myelopoiesis in the Pathogenesis of Myeloid Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,690,224 | August 1, 2021 | July 31, 2027 | PASSEGUE, EMMANUELLE | reporter.nih.gov |
| Spatially resolved, single cell biomarkers of B cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,690,152 | August 1, 2022 | July 31, 2027 | MERCHANT, AKIL | reporter.nih.gov |
| Clinical Significance of MHC Haplotypes in HCT | NIH | National Cancer Institute | 2021 to 2025 | $2,687,420 | March 1, 2003 | August 31, 2028 | PETERSDORF, EFFIE W | reporter.nih.gov |
| Enhancing Innate Immune Reconstitution Post Allogeneic HSCT. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,685,463 | September 1, 2021 | June 30, 2025 | SERODY, JONATHAN S. | reporter.nih.gov |
| Computational and Experimental Modeling of Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,685,262 | January 1, 2022 | December 31, 2026 | GRIFFITH, BOYCE EUGENE | reporter.nih.gov |
| InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | NIH | National Cancer Institute | 2021 to 2025 | $2,685,053 | September 3, 2021 | August 31, 2026 | MCKAY, JAMES DOWLING | reporter.nih.gov |
| Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML | NIH | National Cancer Institute | 2022 to 2025 | $2,684,963 | February 3, 2022 | January 31, 2027 | BINDRA, RANJIT | reporter.nih.gov |
| Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,682,494 | September 15, 2022 | June 30, 2027 | ALMEIDA-PORADA, GRACA DUARTE | reporter.nih.gov |
| PET Imaging of Vaso-Occlussive Crisis in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,679,004 | March 15, 2022 | February 28, 2027 | NOVELLI, ENRICO M | reporter.nih.gov |
| Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia. | NIH | National Cancer Institute | 2022 to 2025 | $2,677,641 | August 1, 2022 | July 31, 2027 | STIEGLITZ, ELLIOT | reporter.nih.gov |
| 1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,676,312 | March 15, 2020 | February 28, 2026 | MCCRAE, KEITH R. | reporter.nih.gov |
| Cellular effects of SARS-CoV-2 in mediating thrombotic susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,674,669 | February 9, 2022 | January 31, 2027 | DAYAL, SANJANA | reporter.nih.gov |
| Selective disruption of histone deacetylase complexes using protein interaction modulators | NIH | National Cancer Institute | 2022 to 2025 | $2,674,355 | February 1, 2022 | January 31, 2027 | VIDAL, MARC | reporter.nih.gov |
| MR-Derived Cerebral Oxygen Metabolism underlying Ischemic Vulnerability in Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,672,673 | August 15, 2015 | June 30, 2025 | FORD, ANDRIA LEE | reporter.nih.gov |
| The role of the innate immune cell cyclooxygenase/prostaglandin system in blood pressureregulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,667,442 | December 20, 2002 | June 30, 2028 | HARRIS, RAYMOND C. | reporter.nih.gov |
| COVID Transmission and Morbidity in Malawi (COVID-TMM) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,666,340 | April 1, 2025 | March 31, 2027 | VALIM, CLARISSA | reporter.nih.gov |
| Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,663,582 | February 15, 2021 | January 31, 2026 | BLAZAR, BRUCE R | reporter.nih.gov |
| BAFF-R CAR T cell therapy for ALL | NIH | National Cancer Institute | 2022 to 2025 | $2,663,058 | April 18, 2022 | March 31, 2027 | WANG, XIULI | reporter.nih.gov |
| Negative regulators of endothelial regeneration in aging lungs and ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,661,375 | June 1, 2022 | March 31, 2026 | ZHAO, YOU-YANG | reporter.nih.gov |
| Sepsis Characterization in Kilimanjaro | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,660,507 | September 23, 2020 | August 31, 2025 | RUBACH, MATTHEW P | reporter.nih.gov |
| Transcriptional Control During Erythropoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,660,464 | September 16, 2013 | October 31, 2025 | RANISH, JEFFREY A | reporter.nih.gov |
| Genetic and molecular basis for SRSF2 mutations in myelodysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,659,317 | August 1, 2015 | April 30, 2029 | BRADLEY, ROBERT K | reporter.nih.gov |
| Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations | NIH | National Cancer Institute | 2022 to 2025 | $2,657,718 | June 15, 2022 | May 31, 2027 | PAPAPETROU, EIRINI | reporter.nih.gov |
| Tie2-driven vascular control in critical illness | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,655,728 | January 16, 2018 | December 31, 2025 | PARIKH, SAMIR M | reporter.nih.gov |
| Clonal Hematopoiesis Aging Resiliency Mechanisms | NIH | National Institute on Aging | 2024 to 2025 | $2,653,601 | August 15, 2024 | June 30, 2029 | BICK, ALEXANDER | reporter.nih.gov |
| A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,649,150 | September 18, 2020 | June 30, 2025 | HEYSELL, SCOTT K | reporter.nih.gov |
| Genetic and Biochemical Studies of KSHV LANA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,646,919 | April 1, 2020 | March 31, 2026 | KAYE, KENNETH M | reporter.nih.gov |
| BC-mediated delivery of thromboprophylaxis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,646,485 | September 1, 2021 | June 30, 2026 | MUZYKANTOV, VLADIMIR R | reporter.nih.gov |
| Improving Outcomes Assessment in Chronic Graft versus Host Disease | NIH | National Cancer Institute | 2022 to 2025 | $2,646,165 | July 18, 2007 | March 31, 2027 | LEE, STEPHANIE J | reporter.nih.gov |
| Enhancement of Brain Dysfunction in Sepsis Survivors by Alzheimer’s Disease Neuropathology | NIH | National Institute on Aging | 2022 to 2025 | $2,646,143 | January 15, 2022 | December 31, 2026 | SINGER, BENJAMIN HERSCHEL | reporter.nih.gov |
| Down Syndrome Early Childhood Omics, Deep Phenotyping, and Epidemiology in Texas: DECODE IT Cohort | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $2,644,869 | September 17, 2024 | May 31, 2029 | LUPO, PHILIP | reporter.nih.gov |
| Training in Trauma and Sepsis Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,643,849 | July 1, 1994 | June 30, 2029 | BILLIAR, TIMOTHY R | reporter.nih.gov |
| Mechanism of sickle cell disease-specific venous thromboembolism | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,643,179 | April 1, 2021 | March 31, 2025 | PAWLINSKI, RAFAL L | reporter.nih.gov |
| Targeted Therapies for Lymphoid Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,642,763 | April 1, 2013 | January 31, 2026 | WOYACH, JENNIFER A. | reporter.nih.gov |
| Novel strategies to understand, predict, and prevent vascular toxicity of targeted CML therapies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,641,307 | January 1, 2021 | December 31, 2025 | JAFFE, IRIS Z | reporter.nih.gov |
| Tumor suppressor reprogramming by EBV through post-translational modification | NIH | National Cancer Institute | 2022 to 2025 | $2,640,070 | September 1, 2022 | August 31, 2028 | ROBERTSON, ERLE S. | reporter.nih.gov |
| Development of CD46 theranostics for imaging and treatment of multiple myeloma | NIH | National Cancer Institute | 2022 to 2025 | $2,633,937 | July 1, 2022 | June 30, 2027 | FLAVELL, ROBERT RICHARD | reporter.nih.gov |
| Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,632,895 | August 1, 2021 | July 31, 2025 | PALMER, ANDRE FRANCIS | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Dana-Farber Cancer Inst | Boston, MA | 77 | $161 million | 0 | $0 |
| Public Health Institute | Oakland, CA | 4 | $157.9 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 125 | $138.2 million | 0 | $0 |
| Emory University | Atlanta, GA | 112 | $136.9 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 67 | $136.7 million | 0 | $0 |
| Washington University | Saint Louis, MO | 117 | $134.4 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 48 | $134.1 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 80 | $133.8 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 131 | $122 million | 0 | $0 |
| Ohio State University | Columbus, OH | 80 | $119.1 million | 0 | $0 |
| Yale University | New Haven, CT | 78 | $117.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 107 | $116.6 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 78 | $116.5 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 66 | $110.7 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 76 | $110 million | 0 | $0 |
| University of Florida | Gainesville, FL | 71 | $106.7 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 81 | $104.4 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 65 | $103 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 75 | $100.5 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 85 | $93.1 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 70 | $89.5 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 51 | $89 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 60 | $86.8 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 70 | $85.6 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 68 | $85.5 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 79 | $84.4 million | 0 | $0 |
| Duke University | Durham, NC | 83 | $83.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 88 | $82.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 63 | $81.3 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 27 | $74.6 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 64 | $70.9 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 81 | $70.8 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 65 | $69.2 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 64 | $67.8 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 59 | $66.2 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 54 | $64 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 47 | $63.2 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 49 | $63.1 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 50 | $62.8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 44 | $62.8 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 61 | $57.6 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 53 | $53.9 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 49 | $52.8 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 38 | $52.7 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 59 | $52.6 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 36 | $50.5 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 49 | $49.2 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 50 | $48.2 million | 0 | $0 |
| University of Chicago | Chicago, IL | 32 | $47.7 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 41 | $43.5 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 39 | $40.8 million | 0 | $0 |
| Versiti Blood Health, Inc. | Milwaukee, WI | 32 | $40.7 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 40 | $40 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 15 | $38.5 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 33 | $36.3 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 28 | $35.8 million | 0 | $0 |
| University of Rochester | Rochester, NY | 35 | $35.8 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 35 | $35.8 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 26 | $35.3 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 12 | $34.9 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 26 | $34.4 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 25 | $30 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 33 | $29.9 million | 0 | $0 |
| Helixbind, Inc. | Boxborough, MA | 10 | $28.1 million | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 7 | $26.8 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 13 | $25.9 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 23 | $25.7 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 22 | $25.4 million | 0 | $0 |
| Feinstein Institute for Medical Research | Manhasset, NY | 19 | $24.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 23 | $23.9 million | 0 | $0 |
| Augusta University | Augusta, GA | 19 | $22.8 million | 0 | $0 |
| Midwest Research Institute | Kansas City, MO | 1 | $22.6 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 24 | $21.9 million | 0 | $0 |
| Oklahoma Medical Research Foundation | Oklahoma City, OK | 9 | $21.4 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 17 | $21.3 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 5 | $21 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 15 | $20.8 million | 0 | $0 |
| Ecog-Acrin Medical Research Foundation | Philadelphia, PA | 1 | $20.6 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 19 | $19.7 million | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 16 | $19.6 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 12 | $18.6 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 20 | $18.5 million | 0 | $0 |
| Westat, Inc. | Bethesda, MD | 1 | $16.7 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 38 | $16.6 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 13 | $16.5 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 15 | $16.1 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 19 | $14.4 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 17 | $14.4 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 7 | $14.3 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 13 | $14.1 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 20 | $13.7 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 12 | $13.7 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 11 | $13.4 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 9 | $13 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 12 | $13 million | 0 | $0 |
| New York Blood Center | New York, NY | 11 | $12.9 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 14 | $12.9 million | 0 | $0 |
| Bloodworks | Seattle, WA | 9 | $12.7 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 14 | $12.5 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 14 | $12.4 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 2,503 | $1,432,755,230 | 0 | $0 |
| 2024 | 2,625 | $1,387,229,469 | 0 | $0 |
| 2023 | 2,690 | $1,417,627,054 | 0 | $0 |
| 2022 | 2,716 | $1,335,387,643 | 0 | $0 |
| 2021 | 2,623 | $1,260,373,914 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.